GamaMabs Pharma and Mayo Clinic will collaborate on a study on the efficacy of GamaMabs’ 3C23K antibody in ovarian patient-derived xenografts (PDX) models
Toulouse, France – November 27, 2014 – GamaMabs Pharma announces the initiation of a collaborative study with Mayo Clinic, Rochester (MN-USA) on its 3C23K monoclonal antibody targeting AMHRII/MISIIR, with Dr. William A. Cliby, M.D, Department of Gynecologic Oncology, and Drs. John Weroha, M.D. and Paul Haluska M.D., Ph.D., Department of Oncology, as its investigators.
The two entities will study the “Efficacy of GamaMabs’ 3C23K Monoclonal Antibody in Ovarian Cancer Patient-Derived Xenografts”, and will leverage Mayo Clinic’s large panel of ovarian cancer PDX and Dr. Cliby’s knowledge of AMHRII/MISIIR in this setting.
In 2008, Mayo Clinic researchers J. Bakkum-Gamez, W. Cliby et al. published in Gynecologic Oncology the largest study to date on Müllerian inhibiting substance type II receptor (MISIIR) “MISIIR: A novel tissue-specific target expressed by gynecologic cancers”. This study reports that MISIIR/AMHRII is highly expressed by a wide variety of gynecologic cancers, including cancers currently without effective systemic therapies.
Mayo Clinic has a panel of more than 250 ovarian cancer PDX.
Jean-François Prost, VP R&D and Strategy GamaMabs Pharma says « Besides its prestige, we are very proud of this opportunity to benefit from the unique Mayo Clinic’s expertise on AMHRII and of its large panel of innovative PDX models. We feel that PDX orthotopic models are the closest to human cancer biology, and the most pertinent tools to demonstrate the efficacy of a drug-candidate ».
About GamaMabs Pharma
GamaMabs Pharma is a French Biotechnology company developing innovative monoclonal antibodies in cancer. GamaMabs’ lead project is the monoclonal antibody (mAb) 3C23K, currently in advanced pre-clinical stage, which targets Anti-Mullerian Human Receptor 2 (AMHRII/MISIIR) in ovarian cancer. Ovarian cancer is responsible for over 50 000 deaths every year in Europe and the United States. The company develops low-fucose antibodies with increased activity through the activation of immune system cells.
Jean-François Prost, VP R&D and Strategy, firstname.lastname@example.org